Cue Biopharma Inc (NASDAQ: CUE) on Friday, plunged -8.25% from the previous trading day, before settling in for the closing price of $0.39. Within the past 52 weeks, CUE’s price has moved between $0.23 and $1.54.
A company in the Healthcare sector has jumped its sales by 15.39% annually for the last half of the decade. The company achieved an average annual earnings per share of 43.75%. With a float of $90.53 million, this company’s outstanding shares have now reached $91.24 million.
Cue Biopharma Inc (CUE) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cue Biopharma Inc is 0.36%, while institutional ownership is 19.79%. The most recent insider transaction that took place on Dec 30 ’25, was worth 99,747. In this transaction Director of this company bought 323,857 shares at a rate of $0.31, taking the stock ownership to the 323,857 shares. Before that another transaction happened on Dec 29 ’25, when Company’s Officer proposed sale 7,230 for $0.26, making the entire transaction worth $1,907.
Cue Biopharma Inc (CUE) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.13 earnings per share (EPS) for the period topping the consensus outlook (set at -0.14) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.19% during the next five years compared to 15.39% growth over the previous five years of trading.
Cue Biopharma Inc (NASDAQ: CUE) Trading Performance Indicators
Cue Biopharma Inc (CUE) is currently performing well based on its current performance indicators. A quick ratio of 1.66 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.47 in one year’s time.
